Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week.
BACKGROUND
Furazolidone is an inexpensive antibiotic that has considerable anti-Helicobacter pylori activity in vitro.


METHODS
Twenty-three patients with culture-proven H. pylori infection were treated for one week with a dual therapy containing omeprazole and furazolidone.


RESULTS
Eradication succeeded in 10 of the first 20 evaluable patients (50%; 95% CI: 27.2-72.8%). This percentage was regarded as too low, and the study was terminated. Side-effects were mild.


CONCLUSIONS
With the possible increase in resistance to metronidazole and clarithromycin world-wide, furazolidone may be useful alternative in the treatment of H. pylori infection. Dual therapy for one week, however, is not sufficient.
Van Zwet
A A
AA
Regional Public Health Laboratory Groningen/Drenthe, The Netherlands.
Thijs
J C
JC
van der Wouden
E J
EJ
Kooy
A
A
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005664:Furazolidone / Q000627:therapeutic use*; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D009853:Omeprazole / Q000627:therapeutic use*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D005664:Furazolidone; D009853:Omeprazole